NCT04914273View on ClinicalTrials.gov

Use of Exhaled Particles to Assess Lung Pharmacokinetics

NACompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 14, 2021

Primary Completion Date

August 3, 2021

Study Completion Date

August 3, 2021

Conditions
HealthyLung Pharmacokinetic
Interventions
DRUG

Inhalation Spray

400 mcg salbutamol administered per metered dose inhaler

DRUG

Tablet

8 mg salbutamol administered per tablet for ingestion

Trial Locations (1)

30625

Fraunhofer Institute for Toxicology and Experimental Medicine, Hanover

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Fraunhofer-Institute of Toxicology and Experimental Medicine

OTHER